MONURIL ® is a drug based on Phosphomycin salt of trometamol
THERAPEUTIC GROUP: Antibacterial for systemic use
Indications MONURIL ® Phosphomycin salt of trometamol
MONURIL ® is indicated in the treatment of nonspecific and acute lower urinary tract infections.
This medicine has also been shown to be effective in the prevention of post-surgical or post-diagnostic cystitis and urethritis.
Mechanism of action MONURIL ® Phosphomycin salt of trometamol
MONURIL ® is a phosphomycin drug, an active ingredient with a strong bactericidal activity against both Gram positive and Gram negative bacteria.
Taken orally, this molecule is rapidly absorbed from the gastro-enteric tract, reaching the various tissues in therapeutic concentrations in particularly short times, being eliminated unchanged through the urine in just 2-4 hours.
The persistence of unchanged phosphomycin in the lower urinary tract allows the drug to carry out its therapeutic action against the pathogenic microorganisms present in this district, replacing the phosphoenolpyruvate and thus seriously compromising the structure and protective capacity of the bacterial wall.
The absence of cross-resistance mechanisms to other drugs active on the bacterial wall, allow Fosfomycin to carry out its therapeutic action in an effective and safe way, thus reducing the onset of pharmacologically multidrug-resistant strains.
Studies carried out and clinical efficacy
PHOSPHOMYCIN AND AMOXICILLIN IN THE PREVENTION OF INFECTIONS OF THE URINARY TRACT
Antimicrob Agents Chemother. 2013 Mar; 57: 1518-20.
Fosfomycin Synergy In Vitro with Amoxicillin, Daptomycin, and Linezolid against Vancomycin-Resistant Enterococcus faecium from Renal Transplant Patients with Infected Urinary Stents.
Descourouez JL, Jorgenson MR, Wergin JE, Rose WE.
Study that demonstrates how the combination of Fosfomycin and Amoxicillin can be effective in the prevention of urinary infections in patients undergoing kidney transplantation.
LOW RESISTANCE TO PHOSPHOMYCIN
J Vet Med Sci. 2012 Dec 19.
Efficacy of Fosfomycin on Escherichia coli Isolated from Bitches with Pyometra.
Inoue I, Shibata S, Fukata T.
Very interesting study that demonstrates how the microbial strains isolated in the cases of Pyometra are generally sensitive to Phosphomycin, thus allowing an effective clinical use.
PHOSPHOMYCIN IN THE PREVENTION OF POST-SURGICAL INFECTIONS OF THE PROSTATE
Urol Int. 2012; 89: 439-44.
The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate.
Ongün S, Aslan G, Avkan-Oguz V.
This work demonstrates how the great clinical efficacy of fosfomycin can guarantee excellent results in terms of post-surgical prevention, reducing the use of other antibiotics, and therefore also the related associated resistance mechanisms.
Method of use and dosage
MONURIL ®
Granules for oral solution of 2 - 3 gr of Phosphomycin per sachet.
The dosage regimen based on MONURIL ® useful in the treatment and prevention of cystitis or other infections of the lower urinary tract should be defined by the physician on the basis of the physiopathological and clinical characteristics of the patient.
In order to optimize the therapeutic efficacy of fosfomycin, it would be advisable to take the drug before going to bed and after emptying the bladder, so that the active principle performs its therapeutic action for a longer time.
Warnings MONURIL ® Phosphomycin salt of trometamol
Before starting treatment with MONURIL ® it would be advisable to undergo a careful medical examination aimed at assessing the patient's clinical conditions, the possible presence of contraindications, and therefore the appropriateness of the therapy.
The efficacy of the drug could be compromised by the intake of drugs active on renal function rather than by active principles on peristalsis.
MONURIL ® contains sucrose, therefore its intake is contraindicated in patients with fructose intolerance, glucose-galactose malabsorption syndrome, sucrase-isomaltase insufficiency and possibly in diabetic patients.
PREGNANCY AND BREASTFEEDING
The use of MONURIL ® during pregnancy should only take place in cases of real necessity and under the strict medical supervision.
The data currently present in the literature do not fully clarify the safety profile of the drug for fetal and infant health.
Interactions
In order to preserve the pharmacokinetic properties of phosphomycin, it would be advisable to avoid the simultaneous intake of drugs active on diuresis, peristalsis, antacids or food.
It is recommended to consult your doctor if it becomes necessary to take other drugs at the same time as MONURIL ®.
Contraindications MONURIL ® Phosphomycin salt of trometamol
The use of MONURIL ® is contraindicated in patients hypersensitive to the active substance or to any of its excipients, in patients with severe renal insufficiency and in all patients undergoing hemodialysis.
Undesirable Effects - Side Effects
Therapy with MONURIL ® could cause the onset, with a certain frequency of diarrhea, nausea, dyspepsia, headache and dizziness
Fortunately rare are instead clinically more relevant manifestations such as asthma, pseudomembranous colitis, adverse reactions of hypersensitivity and hypotension.
Note
MONURIL ® is a drug subject to mandatory medical prescription.
The information on MONURIL ® Fosfomycin trometamol salt published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
